Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK EML4-ALK E6;A20
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon 6 and ALK exon 20). TAE684 inhibited Akt and Erk1/2 phosphorylation in H2228 cells and appeared to induce a cytostatic response.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1194
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/503
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- TAE684
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 18451166
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| TAE684 | Sensitivity | true |